News
MSD has received FDA approval for Enflonsia (clesrovimab-cfor) to prevent respiratory syncytial virus (RSV) in neonates and ...
The EC has approved Alnylam Pharmaceuticals' Amvuttra (vutrisiran) to treat wild-type or hereditary ATTR-CM in adults.
The 17 sitting members of the Advisory Committee on Immunization Practices (ACIP) will be replaced by new members chosen by the Trump administration.
YolTech has received FDA approval for its investigational new drug (IND) application for YOLT-101 to treat HeFH.
In this article, GlobalData examines key reimbursement trends that reflect the current delays to patient access across the ...
The EC has granted approval for a fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) plus venetoclax.
Aytu BioPharma has signed an agreement with Fabre-Kramer Pharmaceuticals to commercialise Exxua in the US market for MDD.
During an FDA panel discussion, the US health secretary prioritised easier routes to market for curative therapies.
Juvenescence has acquired Ro5 to enhance its AI/machine learning capabilities and improve research and development.
The European Commission (EC) has granted marketing authorisation to Sydnexis for its low-dose atropine formulation SYD-101.
Digital innovations such as ePRO and eCOA are streamlining clinical trials, boosting participant engagement, and improving ...
A study found no rise in ADHD cases, though some drugs for the disorder are still in shortage amid high demand.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results